98 related articles for article (PubMed ID: 10169631)
1. Monoclonal gammopathy of undetermined significance.
Clark KT
J Insur Med; 1997; 29(2):136-8. PubMed ID: 10169631
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism.
Gregersen H; Nørgaard M; Severinsen MT; Engebjerg MC; Jensen P; Sørensen HT
Eur J Haematol; 2011 Feb; 86(2):129-34. PubMed ID: 20942842
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Rajkumar SV; Lacy MQ; Kyle RA
Blood Rev; 2007 Sep; 21(5):255-65. PubMed ID: 17367905
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
Srkalovic G; Cameron MG; Rybicki L; Deitcher SR; Kattke-Marchant K; Hussein MA
Cancer; 2004 Aug; 101(3):558-66. PubMed ID: 15274069
[TBL] [Abstract][Full Text] [Related]
6. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal gammopathy of undetermined significance in sarcoidosis. Two case reports.
Sharma AM; Fried J; Sharma OP
Sarcoidosis; 1992 Mar; 9(1):70-2. PubMed ID: 1344048
[TBL] [Abstract][Full Text] [Related]
8. [Multiple myeloma with Sweet disease developing from monoclonal gammopathy of undetermined significance and Sjögren syndrome].
Harada Y; Egi Y; Honda Y; Shirota T; Hayashi T
Rinsho Ketsueki; 2001 Dec; 42(12):1176-80. PubMed ID: 11828720
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal gammopathy of undetermined significance: new insights.
Chen BH
CMAJ; 2002 May; 166(10):1309. PubMed ID: 12041852
[No Abstract] [Full Text] [Related]
10. [Determination of interleukin-6 messenger RNA as malignant progression index in monoclonal gammapathy of undetermined significance].
Mancini R; Palange M; Dionisi MG; De Angelis V; Matteocci A; Strano L
Recenti Prog Med; 1999 Oct; 90(10):522-6. PubMed ID: 10592737
[TBL] [Abstract][Full Text] [Related]
11. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
Gobbi PG; Baldini L; Broglia C; Goldaniga M; Comelli M; Morel P; Morra E; Cortelazzo S; Bettini R; Merlini G
Clin Cancer Res; 2005 Mar; 11(5):1786-90. PubMed ID: 15756000
[TBL] [Abstract][Full Text] [Related]
12. Neuromuscular disorders associated with paraproteinemia.
Hoffman-Snyder C; Smith BE
Phys Med Rehabil Clin N Am; 2008 Feb; 19(1):61-79, vi. PubMed ID: 18194750
[TBL] [Abstract][Full Text] [Related]
13. Sterile abscesses complicating monoclonal gammopathy of undetermined significance.
Mitrevski M; Granata M; Sedati P; Rota F; De Santis A; Remotti D; Callea F; Visentini M
Eur J Haematol; 2008 Sep; 81(3):246. PubMed ID: 18410540
[No Abstract] [Full Text] [Related]
14. Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.
Rossi F; Petrucci MT; Guffanti A; Marcheselli L; Rossi D; Callea V; Vincenzo F; De Muro M; Baraldi A; Villani O; Musto P; Bacigalupo A; Gaidano G; Avvisati G; Goldaniga M; Depaoli L; Baldini L
Clin Cancer Res; 2009 Jul; 15(13):4439-45. PubMed ID: 19509142
[TBL] [Abstract][Full Text] [Related]
15. Lymphoproliferative disorders in chronic hepatitis C.
Idilman R; Colantoni A; De Maria N; Alkan S; Nand S; Van Thiel DH
J Viral Hepat; 2004 Jul; 11(4):302-9. PubMed ID: 15230852
[TBL] [Abstract][Full Text] [Related]
16. Lower bone mineral density in geriatric patients with monoclonal gammopathy of undetermined significance.
Dizdar O; Erman M; Cankurtaran M; Halil M; Ulger Z; Yavuz BB; Ariogul S; Pinar A; Harputluoglu H; Kars A; Celik I
Ann Hematol; 2008 Jan; 87(1):57-60. PubMed ID: 17874101
[TBL] [Abstract][Full Text] [Related]
17. The significance of soluble CD138 in diagnosis of monoclonal gammopathies.
Maisnar V; Tousková M; Tichý M; Krejsek J; Chrobák L; Voglová J; Malý J
Neoplasma; 2006; 53(1):26-9. PubMed ID: 16416009
[TBL] [Abstract][Full Text] [Related]
18. Neuropathies associated with IgG and IgA monoclonal gammopathy.
Nobile-Orazio E; Casellato C; Di Troia A
Rev Neurol (Paris); 2002 Oct; 158(10 Pt 1):979-87. PubMed ID: 12407307
[TBL] [Abstract][Full Text] [Related]
19. [The CBO professional guideline 'monoclonal gammopathy' (paraproteinemia) (revision)].
Buiting AM; Wijermans PW
Ned Tijdschr Geneeskd; 2002 Jul; 146(30):1406-11. PubMed ID: 12174434
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of a population based cohort with monoclonal proteinaemia.
Schaar CG; le Cessie S; Snijder S; Franck PF; Wijermans PW; Ong C; Kluin-Nelemans H
Br J Haematol; 2009 Jan; 144(2):176-84. PubMed ID: 19036113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
